The stock of NxStage Medical, Inc. (NASDAQ:NXTM) is a huge mover today! About 105,794 shares traded hands. NxStage Medical, Inc. (NASDAQ:NXTM) has risen 59.24% since April 22, 2016 and is uptrending. It has outperformed by 53.83% the S&P500.
The move comes after 7 months positive chart setup for the $1.71B company. It was reported on Nov, 25 by Barchart.com. We have $27.21 PT which if reached, will make NASDAQ:NXTM worth $102.60M more.
Analysts await NxStage Medical, Inc. (NASDAQ:NXTM) to report earnings on February, 8. They expect $-0.02 earnings per share, up 50.00% or $0.02 from last year’s $-0.04 per share.
NxStage Medical, Inc. (NASDAQ:NXTM) Ratings Coverage
Out of 6 analysts covering NxStage Medical (NASDAQ:NXTM), 5 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 83% are positive. NxStage Medical has been the topic of 7 analyst reports since November 4, 2015 according to StockzIntelligence Inc. The rating was initiated by BTIG Research with “Buy” on Friday, December 18. Canaccord Genuity maintained NxStage Medical, Inc. (NASDAQ:NXTM) rating on Tuesday, August 2. Canaccord Genuity has “Buy” rating and $26 price target. The firm has “Buy” rating by Sterne Agee CRT given on Friday, December 11. The stock has “Outperform” rating given by Northland Capital on Tuesday, June 28. Piper Jaffray reinitiated NxStage Medical, Inc. (NASDAQ:NXTM) rating on Thursday, March 31. Piper Jaffray has “Overweight” rating and $18.50 price target.
According to Zacks Investment Research, “NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure.”
Insitutional Activity: The institutional sentiment increased to 1.2 in Q2 2016. Its up 0.23, from 0.97 in 2016Q1. The ratio is positive, as 22 funds sold all NxStage Medical, Inc. shares owned while 45 reduced positions. 26 funds bought stakes while 39 increased positions. They now own 61.50 million shares or 4.11% more from 59.07 million shares in 2016Q1.
Jennison Assocs Limited Co owns 1.52 million shares or 0.04% of their US portfolio. Schwab Charles Mgmt last reported 0.01% of its portfolio in the stock. Blackrock last reported 74,020 shares in the company. The Pennsylvania-based Nationwide Fund has invested 0% in NxStage Medical, Inc. (NASDAQ:NXTM). Glenmede Trust Na accumulated 0% or 1 shares. Lord Abbett & Limited Com accumulated 259,467 shares or 0.02% of the stock. Teacher Retirement Of Texas owns 8,958 shares or 0% of their US portfolio. Balyasny Asset Mgmt Ltd Limited Liability Company owns 10,566 shares or 0% of their US portfolio. Deerfield last reported 3.84% of its portfolio in the stock. Moreover, Teachers Advisors has 0% invested in NxStage Medical, Inc. (NASDAQ:NXTM) for 112,655 shares. Deere & Com last reported 20,605 shares in the company. Waddell Reed Financial has 0.01% invested in the company for 222,718 shares. Bancshares Of New York Mellon Corporation last reported 704,763 shares in the company. Moreover, Delta Lloyd Nv has 0.13% invested in NxStage Medical, Inc. (NASDAQ:NXTM) for 175,000 shares. The New York-based Blackrock has invested 0% in NxStage Medical, Inc. (NASDAQ:NXTM).
Insider Transactions: Since September 12, 2016, the stock had 0 insider buys, and 8 selling transactions for $1.41 million net activity. Giannini Daniel A sold $167,416 worth of stock. 3,000 shares with value of $76,530 were sold by Swan Winifred L on Tuesday, November 22. MOORE CRAIG W sold $69,930 worth of NxStage Medical, Inc. (NASDAQ:NXTM) on Monday, September 12. On Wednesday, November 23 the insider Burbank Jeffrey H sold $180,075. Turk Joseph E Jr had sold 1,000 shares worth $25,970. TOWSE MATTHEW W sold 4,300 shares worth $112,789.
More recent NxStage Medical, Inc. (NASDAQ:NXTM) news were published by: Fool.com which released: “Here’s Why NxStage Medical, Inc.’s Stock Is Popping Today” on November 03, 2016. Also Fool.com published the news titled: “Why NxStage Medical, Inc. Guided Lower Today” on February 10, 2016. Fool.com‘s news article titled: “Home and Critical Care Drive NxStage Medical, Inc. Q2 Improvement” with publication date: August 04, 2016 was also an interesting one.
NXTM Company Profile
NxStage Medical, Inc., incorporated on October 20, 1998, is a medical technology company. The Firm is engaged in the development, manufacturing and marketing of services and products for patients suffering from chronic or acute kidney failure. The Firm operates through three divisions: System One, In-Center and Services. The Firm offers its services and products to various markets, such as home, critical care and in-center. The Company’s primary product, the System One, delivers the therapeutic flexibility and clinical benefits associated with dialysis machines that can be used by healthcare professionals and trained lay users alike in various settings, including patient homes, as well as traditional care settings, such as hospitals and dialysis centers. The Firm operates NxStage Kidney Care dialysis centers that treat end-stage renal disease patients directly.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.